Person: AKYÜZ, GÜLSEREN DERYA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
AKYÜZ
First Name
GÜLSEREN DERYA
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Open Access Fracture History in Osteoporosis: Risk Factors and its Effect on Quality of Life(AVES, 2015-01-15) AKYÜZ, GÜLSEREN DERYA; Kuru, Pinar; Akyuz, Gulseren; Cersit, Hulya Peynirci; Celenlioglu, Alp Eren; Cumhur, Ahmet; Biricik, Sefikcan; Kozan, Seda; Goksen, Aylin; Ozdemir, Mikail; Luleci, EmelBackground: Fractures are one of the main outcomes in osteoporosis and have an important effect on the general health status. Aims: The purpose of this study was to determine the effect of major fracture history on quality of life. We also investigated the important risk factors and their effect on bone mineral density and fracture history. Study Design: Cross-sectional study. Methods: We recruited 105 patients who were admitted to an osteoporosis outpatient clinic. Medical history, family history, calcium intake, physical activity level and biochemical tests were evaluated. Lumbar spine and femur neck bone mineral density were measured. The Qualeffo-41 questionnaire was also used for evaluating quality of life. Results: The average age of the 105 patients included in the study was 56.04 +/- 13.73 and 89% of them were post-menopausal women. The average body mass index was 26.84 +/- 5.99, which means that the women were overweight. Also, 48.5% of the patients were diagnosed with osteoporosis and 51.5% of them were diagnosed as low bone density. A total of 34 patients had a fracture history with minor trauma and some of the patients had more than one fracture (12 ankle and foot, 10 forearm, 9 vertebral, 4 hand, 3 hip, 2 rib, 1 tibial). When the patients with and without fracture history were compared, the mean Qualeffo-41 score in patients with fracture was 43.85 +/- 2.57 and in the non-fracture group was 36.27 +/- 2.01. Conclusion: Forearm, ankle and foot fractures can be commonly seen in osteoporosis patients with fracture history. We suggest that it is important to recognise osteoporosis prior to first fracture and disease-specific quality of life assessment should be done.Publication Metadata only Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis(BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK, 2020) AKYÜZ, GÜLSEREN DERYA; Ozsoy-Unubol, Tugba; Akyuz, Gulseren; Mirzayeva, Samaya; Guler, TubaObjectives: This study aims to evaluate pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis (OP). Patients and methods: Between May 2016 and January 2018, a total of 138 patients (mean age 63.78 years; range, 50 to 70 years) with postmenopausal OP were retrospectively analyzed. All patients were previously treated with denosumab (DEN) and parenteral forms of bisphosphonates such as zoledronic acid (ZOL) and ibandronate (IBN). The pain severity was evaluated using the Visual Analog Scale (VAS) and Brief Pain Inventory-Short Form (BPI-SF). The quality of life was evaluated using the Quality of Life Questionnaire of the European Foundation for Osteoporosis (Qualeffo-41). For the evaluation of patient satisfaction, a three-item questionnaire including satisfaction with the medication, route, and frequency of administration was applied. Results: Of the patients, 50 received DEN, 48 received ZOL, and 40 received IBN treatment. There was no significant difference in any of the pain parameters. All domains of the Qualeffo-41 were similar among the three groups. The patients in the DEN group were more satisfied with their medication (DEN: 88%, ZOL: 43.75%, and IBN: 52.5%), its administration route (DEN: 84%, ZOL: 43.8%, and IBN: 57.5%), and the frequency of its administration (DEN: 84%, ZOL: 56.25%, and IBN: 52.5%) (p=0.0001). Conclusion: Neither of the medication showed a superior effect on quality of life. However, patients were more satisfied with medications used in a six-month interval and applied subcutaneously. Of these three treatment options, DEN seems to be a step ahead in terms of patient satisfaction.Publication Metadata only The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain(SPRINGER LONDON LTD, 2007) AKYÜZ, GÜLSEREN DERYA; Ofluoglu, D.; Akyuz, G.; Unay, O.; Kayhan, O.The purpose of this study was to evaluate the efficacy of calcitonin on beta-endorphin levels in female patients experiencing back pain associated with postmenopausal osteoporosis. The secondary purpose was to assess the pain and quality of life in these patients. There were 30 patients with a mean age of 58.2 +/- 5.4 years in the treatment group and 26 patients with a mean age of 58.8 +/- 5.2 years in the placebo group in this randomized, placebo-controlled study. The patients subcutaneously received 100 IU salmon calcitonin or placebo injections and 1,000 mg elementary calcium for 2 weeks. Baseline plasma beta-endorphin levels were measured and repeated after 2 weeks. Patients' pain and quality of life (QOL) were evaluated by using the Visual Analogue Scale, Modified Face Scale, Beck Depression Index, and Nottingham Health Profile. Patients' global assessment of disease activity was also performed at baseline and at the end of the first and second week. We found that plasma beta-endorphin levels in the treatment group were significantly higher than the placebo group at the end of the second week (p < 0.001). Although pain and QOL scores were improved at the end of the second week in both groups (p < 0.05), the improvement in the treatment group was more significant when compared with the placebo group (p < 0.05). Therefore, calcitonin is an analgesic agent, as it increases the plasma beta-endorphin levels in patients with postmenopausal osteoporosis, which consequently improves QOL.Publication Metadata only Relationship between arm span and height in postmenopausal osteoporotic women(SPRINGER HEIDELBERG, 2008) AKYÜZ, GÜLSEREN DERYA; Ofluoglu, Demet; Unlu, Feyza; Akyuz, GulserenOsteoporosis is a progressive systemic skeletal disease characterized by low bone density and microarchitectural deterioration of the bone. A minimum 3-cm difference between arm span and height makes up one of the criteria for suspecting osteoporosis. Therefore, it is easy to determine osteoporotic women by measuring the proportion of height to the arm span. The purposes of this study are to assess the relationship between arm span and height and to compare them in postmenopausal and young healthy women. This was a randomized-controlled, prospective study. There were two groups in this study. Group I included 70 postmenopausal osteoporotic women and group II had 70 healthy young women. Height, weight and arm span of the individuals were measured in all subjects. Bone mineral density and radiological examination of spine were also evaluated. Mean age of postmenopausal women was 64.4 +/- 8.6 years and it was 27.3 +/- 3.5 years in young healthy women. Mean height was 152 +/- 5.1 and 161.5 +/- 5.9 cm in group I and II, respectively. Mean arm span length was 159.6 +/- 6.3 cm in postmenopausal women and 163.5 +/- 6 cm in young healthy women. Mean arm span-height difference was significantly higher in postmenopausal women when compared to healthy young women (7.7 +/- 3.6 and 2 +/- 2.9 cm, respectively, P < 0.001). We suggest that arm span measurements can be used in the estimation of youth height and age-related loss in stature in postmenopausal women.Publication Open Access Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis(YONSEI UNIV COLL MEDICINE, 2003) AKYÜZ, GÜLSEREN DERYA; Aki, S; Eskiyurt, N; Akarirmak, U; Tuzun, F; Eryavuz, M; Alper, S; Arpacioglu, O; Atalay, F; Kavuncu, V; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savas, G; Sendur, OF; Soy, D; Akyuz, GThe aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non-placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 +/- 8.6, with 51.2% in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).Publication Open Access Impact of the Training on the Compliance and Persistence of Weekly Bisphosphonate Treatment in Postmenopausal Osteoporosis: A Randomized Controlled Study(IVYSPRING INT PUBL, 2013) AKYÜZ, GÜLSEREN DERYA; Tuzun, Sansin; Akyuz, Gulseren; Eskiyurt, Nurten; Memis, Asuman; Kuran, Banu; Icagasioglu, Afitap; Sarpel, Tunay; Ozdemir, Ferda; Ozgirgin, Nese; Gunaydin, Rezzan; Cakci, Aytul; Yurtkuran, MerihLong-term patient adherence to osteoporosis treatment is poor despite proven efficacy. In this study, we aimed to assess the impact of active patient training on treatment compliance and persistence in patients with postmenopausal osteoporosis. In the present national, multicenter, randomized controlled study, postmenopausal osteoporosis patients (45-75 years) who were on weekly bisphosphonate treatment were randomized to active training (AT) and passive training (PT) groups and followed-up by 4 visits after the initial visit at 3 months interval during 12 months of the treatment. Both groups received a bisphosphonate usage guide and osteoporosis training booklets. Additionally, AT group received four phone calls (at 2nd, 5th, 8th, and 11th months) and participated to four interactive social/training meetings held in groups of 10 patients (at 3rd, 6th, 9th, and 12th months). The primary evaluation criteria were self-reported persistence and compliance to the treatment and the secondary evaluation criteria was quality life of the patients assessed by 41-item Quality of Life European Foundation for Osteoporosis (QUALEFFO-41) questionnaire.. Of 448 patients (mean age 62.4 +/- 7.7 years), 226 were randomized to AT group and 222 were randomized to PT group. Among the study visits, the most common reason for not receiving treatment regularly was forgetfulness (54.9% for visit 2, 44.3% for visit 3, 51.6% for visit 4, and 43.8% for visit 5), the majority of the patients always used their drugs regularly on recommended days and dosages (63.8% for visit 2, 60.9% for visit 3, 72.1% for visit 4, and 70.8% for visit 5), and most of the patients were highly satisfied with the treatment (63.4% for visit 2, 68.9% for visit 3, 72.4% for visit 4, and 65.2% for visit 5) and wanted to continue to the treatment (96.5% for visit 2, 96.5% for visit 3, 96.9% for visit 4, and 94.4% for visit 5). QUALEFFO scores of the patients in visit 1 significantly improved in visit 5 (37.7 +/- 25.4 vs. 34.0 +/- 14.6, p<0.001); however, the difference was not significant between AT and PT groups both in visit 1 and visit 5. In conclusion, in addition to active training, passive training provided at the 1st visit did not improve the persistence and compliance of the patients for bisphosphonate treatment.